(FM) Oncología
Departamento académico
![Foto de (FM) Oncología](/img/uploaded/1575D5546D141A10EB89AE669C8B8533.jpg)
![Foto de Charité](/img/noimage_org.png)
Charité
Berlín, AlemaniaPublicaciones en colaboración con investigadores/as de Charité (23)
2024
-
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266
-
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
Bulletin du Cancer, Vol. 111, Núm. 3, pp. 277-284
2023
-
Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation
Cancers, Vol. 15, Núm. 13
-
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
Gynecologic Oncology, Vol. 178, pp. 119-129
-
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
Annals of Oncology, Vol. 34, Núm. 8, pp. 681-692
-
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer
Gynecologic Oncology, Vol. 170, pp. 300-308
2022
-
Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’: [ESMO Open Volume 7, Issue 2, April 2022, 100447] (ESMO Open (2022) 7(2), (S2059702922000631), (10.1016/j.esmoop.2022.100447))
ESMO Open
-
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
Therapeutic Advances in Medical Oncology, Vol. 14
-
Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors
ESMO Open, Vol. 7, Núm. 2
2021
-
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma
Virchows Archiv, Vol. 478, Núm. 2, pp. 153-190
-
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Radiotherapy and Oncology, Vol. 154, pp. 327-353
-
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
International Journal of Gynecological Cancer, Vol. 31, Núm. 1, pp. 12-39
-
The systemic treatment of recurrent ovarian cancer revisited
Annals of Oncology, Vol. 32, Núm. 6, pp. 710-725
2020
-
Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: Laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey
International Journal of Gynecological Cancer, Vol. 30, Núm. 6, pp. 819-824
-
Results of the interprofessional and interdisciplinary Berlin round table on patient-reported outcomes, quality of life, and treatment expectations of patients with gynecological cancer under maintenance treatment
International Journal of Gynecological Cancer, Vol. 30, Núm. 10, pp. 1603-1607
2019
-
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
Annals of Oncology, Vol. 30, Núm. 7, pp. 1080-1087
-
Olaparib plus bevacizumab as first-line maintenance in ovarian cancer
New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2416-2428
2018
-
HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?
Annals of Oncology
-
Is there a role for HIPEC in ovarian cancer?
Archives of Gynecology and Obstetrics
-
Safety and dose modification for patients receiving niraparib
Annals of Oncology, Vol. 29, Núm. 8, pp. 1784-1792